Fiorinal w/Codeine and Lorbrena

• Generic Name: aspirin / butalbital / caffeine / codeine
• Dosage Forms: n.a.
• Other Brand Names: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Butalbital, aspirin, caffeine, and codeine combination is used to relieve symptoms of tension (or muscle contraction) headaches. Extended and repeated use of this product is not recommended.

Butalbital belongs to the group of medicines called barbiturates. Barbiturates act in the central nervous system (CNS) to produce their effects.

Aspirin is used to relieve pain and reduce fever in patients. It belongs to the group of medicines known as salicylates and acts on the immune system to reduce inflammation. It is also known as an anti-inflammatory analgesic.

Caffeine is a CNS stimulant that is used with pain relievers to increase their effect. It has also been used for migraine headaches. Codeine belongs to the group of medicine called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.

When butalbital or codeine is used for a long time or in large doses, it may become habit-forming, causing mental or physical dependence. Physical dependence may lead to withdrawal side effects when you suddenly stop taking the medicine. In patients who get headaches, the first symptom of withdrawal may be new (rebound) headaches.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.

• Generic Name: lorlatinib
• Dosage Forms: tablet, film coated
• Other Brand Names: Lorbrena

Lorbrena (lorlatinib) is prescription medicine used to treat a certain type of non-small cell lung cancer that has spread to other parts of the body.

Lorbrena is used only if your cancer has a specific genetic marker (an abnormal "ALK" gene). Your doctor will test you for this gene.

Lorbrena is given after other cancer treatments did not work or have stopped working.

Lorbrena was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.